Previous 10 | Next 10 |
Appoints Richard Miao, Sema4’s Deputy Chief Financial Officer, as interim Chief Financial Officer Reiterates the financial guidance provided on May 12, 2022 STAMFORD, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical ...
The following slide deck was published by Sema4 Holdings Corp. in conjunction with this event. For further details see: Sema4 Holdings (SMFR) Investor Presentation - Slideshow
At 2022 Russell indexes annual reconstitution, following notable health care stocks will be added to and deleted from the Russell 3000 Index. Notable additions: Clover Health Investments (CLOV), Aurinia Pharmaceuticals (AUPH), Nano-X Imaging (NNOX), ADMA Biologics (ADMA),&...
Gainers: Yumanity Therapeutics YMTX +46%. Babylon (BBLN) +11%. Sema4 (SMFR) +11%. Nano-X Imaging (NNOX) +10%. Satsuma Pharmaceuticals (STSA) +10%. Losers: Praxis Precision Medicines PRAX -63%. eFFECTOR Therapeutics (EFTR) -20%. Pear Therapeutics (PEAR) ...
SIOUX FALLS, S.D. and STAMFORD, Conn., June 01, 2022 (GLOBE NEWSWIRE) -- Avera Health , an integrated regional health care system that serves 300 locations across the Upper Midwest, and Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today...
STAMFORD, Conn., May 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate at the following investor conferences: Conference: Jefferies Healthcare Conf...
The following slide deck was published by Sema4 Holdings Corp. in conjunction with their 2022 Q1 earnings call. For further details see: Sema4 Holdings Corp. 2022 Q1 - Results - Earnings Call Presentation
Sema4 Holdings Corp. (SMFR) Q1 2022 Earnings Conference Call May 13, 2022 04:30 p.m. ET Company Representatives Katherine Stueland - Chief Executive Officer Eric Schadt - Founder, President and Chief R&D Officer Isaac Ro - Chief Financial Officer Joel Kaufman - Vice President of Finance a...
Sema4 press release (NASDAQ:SMFR): Q1 GAAP EPS of -$0.31 beats by $0.05. Revenue of $53.9M (-16.0% Y/Y) beats by $3.73M. Reaffirming its previously issued full year 2022 pro forma revenue target of $350 million. Now expects fiscal year 2022 total revenue to be $305-315 million. Expects to end...
Total revenue of $53.9 million 1,300 basis points of sequential adjusted gross margin improvement Reaffirming full year 2022 pro forma revenue target New operating model and focus on efficiencies to reduce 2022 cash burn by an estimated $50 million, extending cas...
News, Short Squeeze, Breakout and More Instantly...
Sema4 Holdings Corp. Company Name:
SMFR Stock Symbol:
NASDAQ Market:
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis ® platforms Company’s common stock will trade on the Nasdaq under new ticker “WGS” effective January 10, 2023 STAMFO...
STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the company will participate in the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland , President and Chief Executive Officer, will del...
STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it ca...